Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.

about

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.

Item

http://www.wikidata.org/entity/Q52562709

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.

@en

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.

@nl

type

Item

label

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.

@en

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.

@nl

prefLabel

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.

@en

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.

@nl

P1476

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.

@en

P2093

Jeremy Pettus

http://www.w3.org/2001/XMLSchema#string

Tricia Santos Cavaiola

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Glucagon and heart in type 2 diabetes: new perspectives

Atherosclerosis — An Inflammatory Disease

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

P304

133-148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DMSO.S154602

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29695924

http://www.w3.org/2001/XMLSchema#string

P932

5905845

http://www.w3.org/2001/XMLSchema#string